Abstract
In this issue, Coronado et al. attempt to improve our understanding of the factors affecting the response to immunotherapy in a large subset of high-risk neuroblastoma with hemizygous deletion of chromosome 11q. By using several computational approaches, the authors study potential transcriptional and post-transcriptional pathways that may affect the response to immunotherapy and further be leveraged therapeutically in a biomarker-directed fashion.
| Original language | English |
|---|---|
| Pages (from-to) | 347-349 |
| Number of pages | 3 |
| Journal | Molecular Oncology |
| Volume | 15 |
| Issue number | 2 |
| DOIs |
|
| State | Published - Feb 2021 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- 11q deletion
- anti-GD2 therapy
- immune checkpoint inhibition
- microRNAs
Fingerprint
Dive into the research topics of 'Refining immunotherapeutic approaches to high-risk neuroblastoma based on tumor genomic profiles'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver